Indications
Voricon is an azole antifungal
medicine. It is indicated for use in patients 12 years of age and older in the
treatment of following fungal infections-
Invasive aspergillosis
Candidemia (nonneutropenic) and
disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds
Esophageal candidiasis
Serious infections caused by
Scedosporium apiospermum and Fusarium Species including Fusarium solani
Patients intolerant of, or
refractory to other therapy.
* রেজিস্টার্ড
চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Pharmacology
Voriconazole is a triazole
antifungal medication used to treat serious fungal infections. Voriconazole
binds and inhibits ergosterol synthesis by inhibiting CYP450-dependent 14-alpha
sterol demethylase. The inhibition of 14-alpha sterol demethylase results in a
depletion of ergosterol in fungal cell membrane.
Dosage & Administration
Oral-
Voriconazole tablet and powder
for suspension are to be taken at least one hour before or one hour following a
meal
At or over 40 kg body weight:
Loading dose regimen is 400 mg or 10 ml every 12 hours (for the first 24 hours)
and maintenance dose (after first 24 hours) is 200 mg or 5 ml twice daily.
Below 40 Kg body weight: Loading dose regimen is 200 mg or 5 ml every 12 hours (for the first 24 hours) and maintenance dose (after first 24 hours) is 100 mg or 2.5 ml twice daily. Or, as directed by the registered physician.
Injection-
Invasive Aspergillosisd :
Loading dose: 6 mg/kg 12 hourly
for the first 24 hours.
Maintenance Dose: 4 mg/kg 12
hourly.
Candidemia in nonneutropenic
patients and other deep tissue Candida infections:
Loading dose: 6 mg/kg 12 hourly
for the first 24 hours.
Maintenance Dose: 3-4 mg/kg 12
hourly.
Scedosporiosis and Fusariosis:
Loading dose: 6 mg/kg 12 hourly
for the first 24 hours.
Maintenance Dose: 4 mg/kg 12
hourly.
* রেজিস্টার্ড
চিকিৎসকের পরামর্শ মোতাবেক ঔষধ সেবন করুন'
Interaction
CYP3A4, CYP2C9 and CYP2C19
inhibitors and inducers: Adjust Voricon dosage and monitor for adverse
reactions or lack of efficacy
Voricon may increase the concentrations
and activity of drugs that are CYP3A4, CYP2C9 and CYP2C19 substrates. Reduce
doses of these other drugs and monitor for adverse reactions
Increase maintenance oral and
intravenous dosage of Voricon with co-administration of Phenytoin or Efavirenz
Contraindications
Known hypersensitivity to
Voriconazole or any other components of this drug-
Co-administration with
terfenadine, astemizole, cisapride, pimozide or quinidine, sirolimus due to
risk of serious adverse reactions
Co-administration with rifampin,
carbamazepine, long-acting barbiturates, efavirenz, ritonavir, rifabutin, ergot
alkaloids and St. John's Wort due to risk of loss of efficacy
Side Effects
The most common side effects are
abdominal pain, anemia, blurred vision, headache, chest pain, nausea and
diarrhea.
Pregnancy & Lactation
There are no adequate and
well-controlled studies in pregnant woman. It should be used during pregnancy
only if the potential benefit justifies the potential risk to the fetus.
Precautions & Warnings
Long term exposure (treatment or
prophylaxis) greater than 180 days requires careful assessment of the
benefit-risk balance. Squamous cell carcinoma of the skin (SCC) has been
reported in relation with long-term Voricon treatment.
Use in Special Populations
The efficacy to the children
under 12 years of age is not established.
Overdose Effects
There is no data found about
overdose of Voricon.
Therapeutic Class
Other Antifungal preparations
Reconstitution
Reconstitution Instructions of
suspension: Shake the bottle well before adding water to loosen the powder. Add
25 ml of boiled and cooled water to the bottle (5 spoons of a provided spoon).
Shake the closed bottle vigorously until powder mixed completely with the
water. Store reconstituted suspension between 15°-30° C. Discard suspension 14
days after reconstitution.
Storage Conditions
Keep out of reach of children.
Store in a dry place, below 25°C temperature and protected from light. Store
Voricon powder for suspension between 2° to 8°C temperature.
No review given yet!
You need to Sign in to view this feature
This address will be removed from this list